New Zealand's medicine crisis worsens, says patient group
New Zealand’s Pharmaceutical Management Agency (Pharmac) has just released its Options for Investment (OFI) list, which includes 36 new medicines since it was updated in July 2021. The OFI includes all medicines that Pharmac would fund if its budget allowed.
Commenting on the OFI, Malcolm Mulholland, chairman of Patient Voice Aotearoa (PVA), said: “We have known for years that there is a medicine crisis in New Zealand. The addition of a whopping 36 medicines to Pharmac’s painfully long medicines waitlist in less than a year shows that the crisis has significantly worsened.”
The updated OFI includes 128 applications that cover 78 medicines and vaccines. The oldest funding application is for the EpiPen, which was first applied for 25 years ago. The average waiting time for medicines on Pharmac’s list is five years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze